Volpara Health Technologies Limited (ASX:VHT) CEO, Dr Ralph Highnam presents on the rollout of the company's software in the US and how it is improving breast cancer screening.
- A MedTech SaaS company improving early detection of breast cancer globally
- Software is regulatory cleared (FDA, CE, TGA), patent protected, clinically validated, users in 36 countries and has over 273 supporting science publications
- Raised $20m from international institutes and existing shareholders
- Will begin the rollout of direct sales into Asia, a rapidly growing market
- Receiving rapid uptake in the US
- Improvements in post installation
For more, watch CEO Dr Ralph Highnam present.